Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:NGM

NGM Biopharmaceuticals (NGM) Stock Price, News & Analysis

NGM Biopharmaceuticals logo

About NGM Biopharmaceuticals Stock (NASDAQ:NGM)

Key Stats

Today's Range
$1.54
$1.57
50-Day Range
$1.52
$1.63
52-Week Range
$0.60
$4.69
Volume
2.39 million shs
Average Volume
1.47 million shs
Market Capitalization
$128.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.55
Consensus Rating
Hold

Company Overview

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company develops NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced metastatic solid tumors; and Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis. It also develops NGM120, an GFRAL antagonist antibody, which is in Phase II clinical trial to treat hyperemesis gravidarum; NGM831 and NGM438 which is in phase I/II clinical trial for the treatment of advanced solid tumors; and NGM621, an monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck to focus primarily on the identification, research and development of collaboration compounds directed to targets in the fields of ophthalmology and cardiovascular or metabolic, or CVM, disease, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.

NGM Biopharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
22nd Percentile Overall Score

NGM MarketRank™: 

NGM Biopharmaceuticals scored higher than 22% of companies evaluated by MarketBeat, and ranked 847th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    NGM Biopharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    NGM Biopharmaceuticals has received no research coverage in the past 90 days.

  • Read more about NGM Biopharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for NGM Biopharmaceuticals are expected to grow in the coming year, from ($0.93) to ($0.78) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of NGM Biopharmaceuticals is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of NGM Biopharmaceuticals is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    NGM Biopharmaceuticals has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for NGM.
  • Dividend Yield

    NGM Biopharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    NGM Biopharmaceuticals does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for NGM.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for NGM Biopharmaceuticals this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, NGM Biopharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    35.90% of the stock of NGM Biopharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    75.74% of the stock of NGM Biopharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about NGM Biopharmaceuticals' insider trading history.
Receive NGM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NGM Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

NGM Stock News Headlines

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong
Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.
Psychedelic Stock Deep Dive: Atai Life Sciences
See More Headlines

NGM Stock Analysis - Frequently Asked Questions

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) posted its earnings results on Thursday, November, 4th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.03. The business earned $18.58 million during the quarter, compared to the consensus estimate of $18.90 million. NGM Biopharmaceuticals had a negative trailing twelve-month return on equity of 77.85% and a negative net margin of 3,223.34%.

NGM Biopharmaceuticals (NGM) raised $100 million in an initial public offering on Thursday, April 4th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Cowen acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that NGM Biopharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Adobe (ADBE), Advanced Micro Devices (AMD), Broadcom (AVGO), CymaBay Therapeutics (CBAY) and PayPal (PYPL).

Company Calendar

Last Earnings
11/04/2021
Today
12/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:NGM
Fax
N/A
Employees
138
Year Founded
1998

Price Target and Rating

Average Stock Price Target
$1.55
High Stock Price Target
$1.55
Low Stock Price Target
$1.55
Potential Upside/Downside
+0.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

Net Income
$-142,380,000.00
Net Margins
-3,223.34%
Pretax Margin
-3,223.34%

Debt

Sales & Book Value

Annual Sales
$4.42 million
Book Value
$1.80 per share

Miscellaneous

Free Float
53,499,000
Market Cap
$128.53 million
Optionable
Optionable
Beta
1.27

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

This page (NASDAQ:NGM) was last updated on 12/23/2024 by MarketBeat.com Staff
From Our Partners